Category: Bio & Healthcare

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has received an ‘Unqualified’ audit opinion from Samil PwC for both consolidated and separate financial statements, reporting FY2025 consolidated revenue of KRW 4.16T and operating profit of KRW 1.17T. 📊 [Key Disclosure Details & Financial Summary] [Consolidated Financial & Earnings Summary] [Separate Financial & Earnings…

Read More “[Disclosure] Celltrion (068270) – Submission of Audit Report / 2026-03-16” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has disclosed a contract for pharmaceutical contract manufacturing worth approximately KRW 279.6B with a pharmaceutical company based in Europe. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Tracking Revenue and Earnings Recognition Following Minimum Quantity Confirmation This disclosure…

Read More “[Disclosure] Samsung Biologics (207940) – Single Sales and Supply Contract / 2026-03-13” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has submitted an IND amendment application to the US FDA for the Phase 3 clinical trial of CT-P55 (a Cosentyx biosimilar candidate). 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of US FDA Approval for Phase 3 IND…

Read More “[Disclosure] Celltrion (068270) – Application for Amendment of Phase 3 Clinical Trial Plan for CT-P55 (Cosentyx Biosimilar) in the US / 2026-03-12” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has issued a corrected disclosure for its Annual General Meeting convocation due to a change in Inside Director nominee (Hyoung-Ki Kim → Min-Chul Shin) and an expansion of treasury share retirement volume. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint)…

Read More “[Disclosure] Celltrion (068270) – Resolution on Convocation of General Shareholders’ Meeting (Correction) / 2026-03-06” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Driven by commercialization milestones for Keytruda SC (Keytruda Qlex) and an upfront payment from the AstraZeneca licensing agreement, ALTEOGEN achieved consolidated revenue of KRW 215.86B (+109.8% YoY) and operating profit of KRW 106.90B (+320.8% YoY) for FY2025. 📊 [Key Disclosure Details & Major Figures Summary] 📝…

Read More “[Disclosure] ALTEOGEN (196170) – Change in Revenue or Profit/Loss Structure Exceeding 30% (15% for Large Corporations) / 2026-02-27” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has clarified that details regarding its reported KRW 300.0B drug product (DP) plant investment in Yesan, Chungnam remain unconfirmed following a Memorandum of Agreement (MOA), with a re-disclosure scheduled by August 25, 2026. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up…

Read More “[Disclosure] Celltrion (068270) – Explanation regarding Rumors or News Reports (Unconfirmed) / 2026-02-26” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has disclosed the submission of its Audit Report for FY2025, receiving an ‘Unqualified’ audit opinion from its external auditor. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verifying Potential Financial Statement Changes During Shareholder Meeting Approval The financial…

Read More “[Disclosure] Samsung Biologics (207940) – Audit Report Submission / 2026-02-25” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary ALTEOGEN will participate in the ‘KIS Investors Conference 2026 Asia’ sponsored by Korea Investment & Securities in Hong Kong and Singapore to present its business status, key technologies, and R&D pipeline plans to foreign institutional investors. 📊 [Key Disclosure Details & Major Figures Summary] 📝 Editor’s…

Read More “[Disclosure] ALTEOGEN (196170) – Investor Relations (IR) Host / 2026-02-20” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary The Incheon District Court has dismissed all applications filed by Yoon OO and 1,230 others requesting permission to convene an Extraordinary General Meeting of Shareholders due to a lack of standing. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification…

Read More “[Disclosure] Celltrion (068270) – Judgment / Decision on Lawsuit / 2026-02-19” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion’s Board of Directors has resolved to convene the 35th Annual General Meeting of Shareholders on March 24, 2026, to vote on financial statements, director appointments, cumulative voting adoption, and treasury share retirement plans. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up…

Read More “[Disclosure] Celltrion (068270) – Resolution on Convocation of General Shareholders’ Meeting / 2026-02-12” »